Skadden is advising Valeant Pharmaceuticals International, Inc. on the $1 billion acquisition of Sprout Pharmaceuticals, Inc. by Valeant's wholly owned subsidiary, announced August 20. On August 18, Sprout received approval from the U.S. Food and Drug Administration of its new drug application for flibanserin.

BACK TO TOP